Therapeutic Dilemmas in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Diffuse Alveolar Hemorrhage and Venous Thromboembolism

March 1, 2026ACR Open RheumatologyOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to address the complexities in treating diffuse alveolar hemorrhage and venous thromboembolism in patients with AAV.
Evaluated severity of diffuse alveolar hemorrhage (DAH) in patients.
Considered additional organ manifestations associated with AAV.
Applied risk stratification for presenting venous thromboembolism (VTE).
Management challenges are influenced by the severity of DAH.
Risk stratification aids in tailoring interventions for VTE.
The presence of additional organ involvement complicates treatment decisions.

Answers are grounded in this paper and cite their sources.

Observational insights guide treatment challenges in diffuse alveolar hemorrhage and venous thromboembolism, emphasizing severity and risk factors.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Ediboglu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share